Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Response from CEO, CHAI about the Quick Start program in November 2016
Response from CEO, CHAI about the Quick Start program in November 2016
Please click here
December 21, 2016
/
News
Share
the Post
Related
Posts
Pricing of Indian generic sofosbuvir, 30th Jan,2016
Factsheet on updated WHO guidelines for the screening, care and treatment of persons with hepatitis C infection from TREAT Asia/amfAR
Patent Situation of The Key Product for Treatment of Hepatitis C: DACLASTAVIR – WHO working paper, revised version, Oct 2014
Flawed patents on hepatitis C drugs latest to be challenged in global push for access
20 YEARS AFTER THE TRIPS AGREEMENT, U.S. GOVERNMENT SCORES MASSIVE VICTORY FOR BIG PHARMA IN TPP DEAL
Availability and Pricing of Generic Sofosbuvir in India – Updated 10 September 2015
Part 2: How is hepatitis C treated?
Patent Situation of The Key Product For Treatment of Hepatitis C: SOFOSBUVIR – WHO working paper, updated 2015
